Dr. Evan G. Dick is the Sr. VP of R&D at Centrexion Therapeutics.
Dr Dick is 69, he's been the Sr. VP of R&D of Centrexion Therapeutics since . There are no older and 5 younger executives at Centrexion Therapeutics.
Evan's mailing address filed with the SEC is 2001 MARKET STREET, SUITE 3915, UNIT #15, PHILADELPHIA, PA, 19103.
Over the last 3 years, insiders at Centrexion Therapeutics have traded over 0$ worth of Centrexion Therapeutics stock and bought 152,118 units worth 245,330$ . The most active insiders traders include Richard J Berman、Martin A. Lehr、Linda West. On average, Centrexion Therapeutics executives and independent directors trade stock every 32 days with the average trade being worth of 21,702$. The most recent stock trade was executed by Martin A. Lehr on 21 February 2023, trading 5,823 units of CNTX stock currently worth 4,891$.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Centrexion Therapeutics executives and other stock owners filed with the SEC include: